LVTX · Lava Therapeutics NV - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $6.99M | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $8.28M | $5.96M | $5.65M | - | - | - | - | - | - | - |
| SG&A | $3.06M | $3.44M | $3.38M | - | - | - | - | - | - | - |
| Total Operating Expenses | $7.55M | $9.39M | $9.03M | - | - | - | - | - | - | - |
| D&A | - | - | $144.0K | - | - | - | - | - | - | - |
| Operating Income | ($11.34M) | ($9.39M) | ($2.04M) | - | - | - | - | - | - | - |
| Interest Expense | $100.0K | $0 | $100.0K | - | - | - | - | - | - | - |
| Income Tax | $96.0K | $86.0K | $69.0K | - | - | - | - | - | - | - |
| Net Income | ($12.33M) | ($8.30M) | ($608.0K) | - | - | - | - | - | - | - |
| EPS - Basic | ($0.46) | ($0.32) | ($0.02) | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.46) | ($0.32) | ($0.02) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49.66M | $26.38M | $39.67M | $35.02M | $44.23M | $100.33M | $90.87M | $15.82M | $7.34M | $7.34M |
| Accounts Receivable | - | - | - | - | $1.46M | $3.25M | $363.0K | $1.14M | $69.0K | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.70M | $1.43M | $1.52M | $2.72M | $4.45M | $3.96M | $2.55M | $934.0K | $422.0K | - |
| Current Assets | $51.91M | $60.49M | $69.78M | $79.30M | $98.90M | $140.53M | $136.50M | $18.22M | $7.62M | - |
| Total Assets | $51.91M | $60.55M | $71.16M | $80.83M | $101.67M | $143.43M | $139.25M | $20.49M | $8.80M | - |
| Current Liabilities | $4.23M | $5.61M | $10.37M | $18.01M | $14.89M | $21.95M | $11.25M | $7.33M | $1.42M | - |
| Long-term Debt | - | - | - | $4.89M | $5.28M | - | - | - | - | - |
| Total Liabilities | $39.23M | $40.61M | $45.37M | $53.09M | $50.31M | $57.38M | $20.88M | $12.87M | $2.95M | - |
| Stockholders' Equity | $12.68M | $42.92M | $25.78M | $27.75M | $51.36M | $86.12M | $118.37M | $7.62M | $5.84M | $5.84M |
| Retained Earnings | ($194.28M) | ($187.09M) | ($178.45M) | ($174.97M) | ($149.86M) | ($108.07M) | ($78.73M) | ($33.39M) | ($13.70M) | - |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($843.0K) | - | - | - | - | - | - | - |
| Investing Cash Flow | - | - | $694.0K | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $8.0K | - | - | - | - | - | - | - |
| CapEx | - | - | $23.0K | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | ($866.0K) | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 | Q4 '21 | Q4 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -29.1% | - | - | - | - | - | - | - |
| EBITDA margin | - | - | -27.1% | - | - | - | - | - | - | - |
| Net margin | - | - | -8.7% | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | -12.4% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 1.42 | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 80.8% | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | 48.3% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -23.7% | -13.7% | -0.9% | - | - | - | - | - | - | - |
| Return on equity | -97.2% | -19.3% | -2.4% | - | - | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 12.27 | 10.78 | 6.73 | 4.40 | 6.64 | 6.40 | 12.14 | 2.48 | 5.35 | - |
| Quick ratio | 12.27 | 10.78 | 6.73 | 4.40 | 6.64 | 6.40 | 12.14 | 2.48 | 5.35 | - |
| Cash ratio | 11.74 | 4.70 | 3.83 | 1.94 | 2.97 | 4.57 | 8.08 | 2.16 | 5.15 | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | 0.18 | 0.10 | - | - | - | - | - |
| Debt / Assets | - | - | - | 0.06 | 0.05 | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -113.4x | - | -20.4x | - | - | - | - | - | - | - |
| Equity multiplier | 4.09 | 1.41 | 2.76 | 2.91 | 1.98 | 1.67 | 1.18 | 2.69 | 1.51 | - |
| Liabilities / Assets | 0.76 | 0.67 | 0.64 | 0.66 | 0.49 | 0.40 | 0.15 | 0.63 | 0.34 | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.10 | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -46.0% | -40.4% | -27.2% | 1453.2% | 30.4% | - | -62.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$100.0K totalManufacturing Technology Transfer Activities$100.0K · 100.0%
Geographic
$11.98M totalNL$11.98M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing LAVA Therapeutics NV against the 5 most active filers in the same SIC group.